We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Use of nonhuman primate models to develop mucosal AIDS vaccines.
- Authors
Genescà, Meritxell; Miller, Christopher J
- Abstract
The HIV vaccines tested in the halted Step efficacy trial and the modestly successful phase 3 RV144 trial were designed to elicit strong systemic immune responses; therefore, strategies to direct immune responses into mucosal sites should be tested in an effort to improve AIDS vaccine efficacy. However, as increased CD4(+) T-cell activation and recruitment to mucosal sites have the potential to enhance HIV transmission, mucosal immune responses to HIV vaccines should primarily consist of effector CD8(+) T cells and plasma cells. Controlling the level of mucosal T-cell activation may be a critical factor in developing an effective mucosal AIDS vaccine. Immunization routes and adjuvants that can boost antiviral immunity in mucosal surfaces offer a reasonable opportunity to improve AIDS vaccine efficacy. Nonhuman primate models offer the best system for preclinical evaluation of these approaches.
- Publication
Current HIV/AIDS reports, 2010, Vol 7, Issue 1, p19
- ISSN
1548-3576
- Publication type
Journal Article
- DOI
10.1007/s11904-009-0035-7